Oncoinvent ASA: Resolution to increase the share capital in connection with settlement of underwriting fee

05 Dec 2025 13:13 CET

5 December 2025: Reference is made to the stock exchange announcements published
by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025, and
subsequent announcements, regarding the contemplated fully underwritten rights
issue of 260,000,000 new shares in the Company (the "Offer Shares") raising
gross proceeds of NOK 130 million (the "Rights Issue").

In connection with the Rights Issue, a total of 31,199,997 new shares, each at a
subscription price of NOK 0.50 (the "Underwriting Commission Shares") shall be
delivered to the underwriters pursuant to the subscription and underwriting
agreements dated 30 June 2025 as settlement of their entitlement to underwriting
fee under said agreements.

In accordance with the authorisation granted to the board of directors at the
extraordinary general meeting held on 4 August 2025, the board of directors has
today resolved to increase the share capital of the Company by NOK 15,599,998.50
by the issuance of 31,199,997 new shares, each with a nominal value of NOK 0.5
and a subscription price of NOK 0.50. The subscription price of NOK 0.50 per
Underwriting Commission Share is equal to the subscription price in the Rights
Issue.

The share capital increase relating to the issuance of the Underwriting
Commission Shares is expected to be registered with the Norwegian Register of
Business Enterprises on or about 9 December 2025, and the Underwriting
Commission Shares are expected to be delivered to the underwriters on or about
10 December 2025.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email: soug@oncoinvent.com

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases in the peritoneum post-surgery, harnessing the benefits of
modern radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. One Phase 1 trial and one Phase 1/2a
trial have been completed and one randomized Phase 2 trial in ovarian cancer is
currently ongoing in the US and Europe. Early clinical efficacy data are highly
encouraging, and no serious toxicity or safety concerns have been reported to
date. Oncoinvent runs a state-of-the-art manufacturing facility to produce drug
products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo
Stock Exchange.

About Radspherin®

Radspherin® is an innovative internal radiation therapy designed to directly
target microscopic metastases in the abdominal cavity following surgery.
Radspherin® is currently in development as a post-surgical treatment for
patients with cancer that has spread to the abdominal cavity - a group with very
limited treatment options today. The drug candidate offers a distinctly unique
therapeutic approach with several differentiating features, including the use of
radium-224, single-dose treatment with a sustained therapeutic effect, non
-systemic administration, direct targeting and an exceptional dose-to-tumor
ratio, maximizing efficacy while limiting harm to healthy tissue

More information:
Access the news on Oslo Bors NewsWeb site